In a large multicentre trial, with a retrospective training cohort (N = 677) and a prospective validation cohort (N = 1225), MPS had a greater detection rate for PCa overall and specifically for Gleason score >6 (AUC = 0.772) compared to PSA (AUC = 0.651), PSA plus T2:ERG (AUC = 0.747) and PSA plus PCA3 (AUC = 0.772).76 The gene discussed is KLK3; the disease is posterior cortical atrophy.